Abstraction Health
Peter Attia

Does Peter Attia recommend Berberine?

Peter Attia recommends Berberine in some contexts, but has also raised cautions.

Published research rates it moderate evidence. Of Peter Attia's 73 tracked claims, 31 are supported or partially supported by studies on PubMed.

🟡Moderate Evidence

Evidence last reviewed May 2026

73
Tracked claims
31
Supported / partial
20
Research studies

Peter Attia on Berberine73 claims

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

For a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, berberine would be a reasonable consideration under medical supervision with attention to drug interactions.

Partially supportedHigh confidence

The provided literature base includes a review specifically examining berberine as an alternative or add-on therapy to metformin (PMID: 34801530) and multiple meta-analyses and reviews addressing berb…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

For a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, berberine would be a reasonable consideration under medical supervision with attention to drug interactions.

Partially supportedHigh confidence

Several RCTs in the provided literature (PMIDs 18442638, 33024120, 34923903, 39998703) examine berberine in type 2 diabetes populations, lending biological plausibility to its use as a glucose-lowerin…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

Berberine would be a reasonable consideration for a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, but only under medical supervision with attention to drug interactions — not as a casual supplement purchase.

Partially supportedHigh confidence

The evidence supports berberine's efficacy for glucose and lipid management in insulin resistance and type 2 diabetes. The RCT (PMID: 18442638) directly compared berberine to metformin (0.5g TID, n=36…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

For a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, berberine would be a reasonable consideration under medical supervision with attention to drug interactions.

Partially supportedHigh confidence

The available literature includes a meta-analysis (PMID 32379652) and several reviews (notably PMID 34801530 reviewing berberine as alternative or add-on therapy to metformin) that collectively sugges…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

For a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, berberine would be a reasonable consideration under medical supervision with attention to drug interactions.

Partially supportedHigh confidence

The RCT by Zhang et al. (PMID 18442638) directly supports berberine's glucose-lowering efficacy in type 2 diabetes, showing comparable effects to metformin (0.5g TID) in 36 newly diagnosed patients. T…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

For a patient who is insulin resistant or has mild type 2 diabetes and cannot tolerate metformin, berberine would be a reasonable consideration under medical supervision with attention to drug interactions.

Partially supportedHigh confidence

The available literature includes a meta-analysis (PMID 32379652) on berberine's effects on obesity indices and a review explicitly comparing berberine as an alternative or add-on to metformin (PMID 3…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Direct recommendation

If I had a patient who was insulin resistant or had mild type 2 diabetes and couldn't tolerate metformin, berberine would be a reasonable consideration — but under medical supervision with attention to drug interactions, not as a casual supplement purchase.

Extracted claim

Berberine would be a reasonable consideration for an insulin-resistant or mildly diabetic patient who cannot tolerate metformin, but only under medical supervision with attention to drug interactions — not as a casual supplement purchase.

Partially supportedHigh confidence

The evidence supports berberine's efficacy for glucose and lipid metabolism in insulin-resistant and type 2 diabetic populations. The RCT (PMID 18442638) directly compared berberine to metformin (0.5g…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

The glucose-lowering effect sizes of berberine are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Insufficient evidence to assessHigh confidence

None of the 10 provided studies directly report key findings, populations, or limitations related to berberine's glucose-lowering effects in type 2 diabetes or prediabetes, as all 'Key finding,' 'Popu…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

The glucose-lowering effect sizes of berberine are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Partially supportedHigh confidence

The provided literature includes RCTs (e.g., PMID 18442638, 33024120, 39998703) and a meta-analysis (PMID 32690176) that are directly relevant to berberine's glucose-lowering effects in type 2 diabete…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes.

Insufficient evidence to assessHigh confidence

The expert's claim specifically references a meta-analysis of RCTs comparing berberine to metformin for fasting glucose and HbA1c reduction in type 2 diabetes. While the provided literature includes r…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

The glucose-lowering effect sizes of berberine are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Insufficient evidence to assessHigh confidence

None of the 10 retrieved studies directly report key findings, populations, or limitations relevant to berberine's glucose-lowering effect in type 2 diabetes or prediabetes, as all key finding fields…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes.

Insufficient evidence to assessHigh confidence

None of the 10 retrieved studies directly address the specific claim that a meta-analysis of RCTs found berberine reduces fasting glucose and HbA1c comparably to metformin in type 2 diabetes. While PM…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes.

Insufficient evidence to assessHigh confidence

None of the 10 retrieved studies directly address the specific claim that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes. While one review (PMID: 3480…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes.

Insufficient evidence to assessHigh confidence

None of the 10 retrieved studies directly address the specific claim that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes patients via a meta-analysis…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

The glucose-lowering effect sizes of berberine are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Insufficient evidence to assessHigh confidence

None of the 10 provided studies directly address berberine's glucose-lowering effects in type 2 diabetes or prediabetes populations — the core of Attia's claim. The retrieved literature focuses primar…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine reduces fasting glucose and HbA1c at levels comparable to metformin in type 2 diabetes.

Partially supportedHigh confidence

The provided literature includes an RCT (PMID: 18442638) directly comparing berberine to metformin (0.5g three times daily) in 36 newly diagnosed type 2 diabetes patients, finding comparable hypoglyce…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

The glucose-lowering effect sizes of berberine are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Partially supportedHigh confidence

The RCT by Zhang et al. (PMID 18442638) directly supports the claim, showing berberine's hypoglycemic effect was comparable to metformin (0.5g TID) in 36 newly diagnosed type 2 diabetes patients over…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin. The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

A meta-analysis of RCTs found berberine produces reductions in fasting glucose and HbA1c comparable to metformin in people with type 2 diabetes.

Partially supportedHigh confidence

The provided evidence includes an RCT (PMID: 18442638) that directly compared berberine to metformin (0.5g three times daily) in 36 newly diagnosed type 2 diabetes patients, showing comparable hypogly…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Evidence-backed claim

A meta-analysis of randomized controlled trials found reductions in fasting glucose and HbA1c comparable to metformin. The effect sizes are real and clinically meaningful for people with type 2 diabetes or prediabetes.

Extracted claim

A meta-analysis of randomized controlled trials found that berberine produces reductions in fasting glucose and HbA1c comparable to metformin in people with type 2 diabetes.

Partially supportedHigh confidence

The RCT by Zhang et al. (PMID: 18442638) directly compared berberine to metformin (0.5g three times daily) in 36 newly diagnosed type 2 diabetes patients over 3 months and found comparable hypoglycemi…

Peter Attia
Peter Attia
Early Medical / The Drive Podcast
Caution / warning

it gets packaged and marketed in ways that I think outrun the evidence

Extracted claim

Berberine is marketed in ways that outrun the available evidence.

Partially supportedHigh confidence

Attia's caution claim is partially supported by the evidence base provided. The available studies include several moderate-quality RCTs and reviews on berberine's effects on type 2 diabetes, lipid pro…

Other supplements Peter Attia discusses

Claims are extracted from publicly available podcasts and videos, attributed to their source, and compared against PubMed research. This is educational information only — consult a healthcare provider before starting any supplement.

Back to Peter Attia